Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.67 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.58 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.58 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.58 |
| ▸ | HTR1D | P28221 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | HTR6 | P50406 | 5/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL27796071 | 0.96 | HTR2A (0.93) | HTR2AGPR84KEAP1NFE2L2ADRB2 | |
| SCHEMBL7004405 | 0.85 | HTR2A (0.73) | HTR2AGPR84KEAP1NFE2L2CA2 | |
| SCHEMBL29585828 | 0.85 | HTR2A (0.73) | HTR2AGPR84KEAP1NFE2L2CA2 | |
| SCHEMBL5212531 | 0.85 | HTR2A (0.73) | HTR2AGPR84KEAP1NFE2L2CA2 | |
| SCHEMBL9889542 | 0.83 | HTR2A (0.71) | HTR2AGPR84KEAP1NFE2L2CA2 | |
| SCHEMBL5402680 | 0.81 | HTR2A (0.69) | HTR2AGPR84KEAP1NFE2L2CA2 | |
| SCHEMBL18328036 | 0.81 | HTR2A (0.69) | HTR2AGPR84KEAP1NFE2L2CA2 | |
| SCHEMBL5598636 | 0.81 | HTR2A (0.69) | HTR2AGPR84KEAP1NFE2L2CA2 | |
| SCHEMBL9206509 | 0.81 | HTR2A (0.69) | HTR2AGPR84KEAP1NFE2L2CA2 | |
| SCHEMBL11359977 | 0.81 | HTR2A (0.69) | HTR2AGPR84KEAP1NFE2L2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 389 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| CN-119614279-A | Energy-saving gear lubricating oil and preparation method thereof | 安徽中天石化股份有限公司 | 2025-03-14 | — | — | CN | claimed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| EP-4358962-A1 | TREATMENT FOR AUTOIMMUNE DISEASES | LDN Pharma Limited (GB) | 2024-05-01 | — | — | EP | claimed |
| WO-2023081842-A2 | ALTERNATIVE BIOSYNTHESIS PATHWAYS FOR THE PRODUCTION OF PSILOCYBIN AND INTERMEDIATES OR SIDE PRODUCTS | MIAMI UNIVERSITY (US) | 2023-05-11 | — | — | WO | claimed |
| WO-2023076135-A1 | N,N-DIMETHYLTRYPTAMINE (DMT) CRYSTALLINE PRODUCTS AND METHODS OF MAKING THE SAME | PSILERA INC. (US) | 2023-05-04 | — | — | WO | claimed |
| CN-115850269-A | Tetrahydro-beta-carboline compound and preparation method and application thereof | 南京工业大学 | 2023-03-28 | — | — | CN | claimed |
| EP-4121045-A1 | CRYSTALLINE NORPSILOCIN COMPOUNDS | Caamtech, Inc. (US) | 2023-01-25 | — | — | EP | claimed |
| WO-2022269267-A1 | TREATMENT FOR AUTOIMMUNE DISEASES | LDN Pharma Limited (GB) | 2022-12-29 | — | — | WO | claimed |
| EP-4031671-A1 | YEAST CELLS AND METHODS FOR PRODUCTION OF TRYPTOPHAN DERIVATIVES | Danmarks Tekniske Universitet (DK) | 2022-07-27 | — | — | EP | claimed |
| WO-2021188812-A1 | CRYSTALLINE NORPSILOCIN COMPOUNDS | CAAMTECH, INC. (US) | 2021-09-23 | — | — | WO | claimed |
| WO-2021052989-A1 | YEAST CELLS AND METHODS FOR PRODUCTION OF TRYPTOPHAN DERIVATIVES | DANMARKS TEKNISKE UNIVERSITET (DK) | 2021-03-25 | — | — | WO | claimed |
| EP-0251938-B1 | STEREOSPECIFIC PROCESS FOR THE SYNTHESIS OF INDOLE DERIVATIVES | SANOFI (FR) | 1991-11-06 | — | — | EP | claimed |
| EP-0251938-A1 | Stereospecific process for the synthesis of indole derivatives | SANOFI (FR) | 1988-01-07 | — | — | EP | claimed |
| US-20260116851-A1 | 2-(2,5-DIETHOXY-4-(ETHYLTHIO)PHENYL)ETHANE-1-AMINIUM CHLORIDE | CAAMTECH INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260083759-A1 | Combinations Comprising Psychedelics for the Treatment of Schizophrenia and Other Neuropsychiatric and Neurologic Disorders | HADASIT MED RES SERVICE (IL) | 2026-03-26 | — | — | US | disclosed |
| EP-0092450-A1 | Tryptamine derivatives active on the cardiovascular system, and process for their preparation | SANOFI S.A. (FR) | 1983-10-26 | — | — | EP | disclosed |
| US-4183858-A | DECARBOXYLASE INHIBITORS | MERRELL TORAUDE ET COMPAGNIE (FR) | 1980-01-15 | — | — | US | disclosed |
| US-4180509-A | ENZYME INHIBITORS, PARKINSON*S DISEASE | MERRELL TORAUDE ET COMPAGNIE (FR) | 1979-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083759-A1 | Combinations Comprising Psychedelics for the Treatment of Schizophrenia and Other Neuropsychiatric and Neurologic Disorders | BDNF, NTRK2, GRIN2A | HTR2A 33/4885GPR84 178/4885KEAP1 4170/4885 |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | HTR2A 14/4885GPR84 1172/4885KEAP1 4308/4885 |
| US-20260116851-A1 | 2-(2,5-DIETHOXY-4-(ETHYLTHIO)PHENYL)ETHANE-1-AMINIUM CHLORIDE | PKD2, PKD1, ALG3 | HTR2A 1623/4885GPR84 4799/4885KEAP1 3883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.